US 11,890,277 B2
Ophthalmic composition
Gregory I. Ostrow, San Diego, CA (US); Kenneth J. Widder, Rancho Santa Fe, CA (US); and David S. Baker, Carlsbad, CA (US)
Assigned to SYDNEXIS, INC., Del Mar, CA (US)
Filed by Sydnexis, Inc., Del Mar, CA (US)
Filed on Nov. 16, 2022, as Appl. No. 18/055,940.
Application 18/055,940 is a continuation of application No. 17/097,930, filed on Nov. 13, 2020, granted, now 11,596,625.
Application 17/097,930 is a continuation of application No. 16/224,286, filed on Dec. 18, 2018, granted, now 10,864,208, issued on Dec. 15, 2020.
Application 16/224,286 is a continuation of application No. 15/895,933, filed on Feb. 13, 2018, granted, now 10,201,534, issued on Feb. 12, 2019.
Application 15/895,933 is a continuation of application No. 15/661,816, filed on Jul. 27, 2017, granted, now 10,076,515, issued on Sep. 18, 2018.
Application 15/661,816 is a continuation of application No. 15/208,537, filed on Jul. 12, 2016, granted, now 9,770,447, issued on Sep. 26, 2017.
Application 15/208,537 is a continuation of application No. 14/726,139, filed on May 29, 2015, granted, now 9,421,199, issued on Aug. 23, 2016.
Claims priority of provisional application 62/151,926, filed on Apr. 23, 2015.
Claims priority of provisional application 62/096,433, filed on Dec. 23, 2014.
Claims priority of provisional application 62/016,502, filed on Jun. 24, 2014.
Prior Publication US 2023/0093205 A1, Mar. 23, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/46 (2006.01); A61K 9/00 (2006.01); A61K 47/02 (2006.01)
CPC A61K 31/46 (2013.01) [A61K 9/0048 (2013.01); A61K 47/02 (2013.01)] 20 Claims
 
1. A stabilized ophthalmic composition for treating pre-myopia, myopia, or progression of myopia, comprising from about 0.001 wt % to about 0.05 wt % of atropine or atropine sulfate and deuterated water, wherein the stabilized ophthalmic composition further comprises a buffering agent at a pD from about 4.2 to about 7.9, wherein the stabilized ophthalmic composition is a liquid, wherein the buffering agent has a buffer capacity sufficient to maintain the pD of the solution between about 4.2 to about 7.9 for an extended period of time of at least 1 month.